A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec200 Product in the Treatment of Relapsed/Refractory Multiple Myeloma
The LVIVO-TaVec200 product is positioned to address a significant unmet need in the treatment of relapsed/refractory multiple myeloma, particularly for patients who have failed at least three lines of prior therapies. The study is being conducted by The First Affiliated Hospital with Nanjing Medical University in collaboration with Nanjing Legend Biotech Co., indicating a strategic partnership that may enhance development capabilities. The market for multiple myeloma therapies is competitive, with several established players; however, the unique mechanism of action targeting GPRC5D could provide a differentiated offering. The trial is currently recruiting, with an estimated completion date in 2029, suggesting a long-term investment horizon for stakeholders. Diligence should focus on the safety profile and potential market entry barriers, including regulatory pathways and existing competitive therapies.
Indication: Multiple Myeloma
Modality: protein therapy
Target: GPRC5D (G protein-coupled receptor class C group 5 member D) - targeting this receptor may enhance the efficacy of the treatment in relapsed/refractory multiple myeloma.
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 07, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: GPRC5D (G protein-coupled receptor class C group 5 member D) - targeting this receptor may enhance the efficacy of the treatment in relapsed/refractory multiple myeloma.
View original source fields
Condition raw: Multiple Myeloma
Condition normalized: Multiple Myeloma
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: GPRC5D (G protein-coupled receptor class C group 5 member D) - targeting this receptor may enhance the efficacy of the treatment in relapsed/refractory multiple myeloma.
Target normalized: GPRC5D (G protein-coupled receptor class C group 5 member D) - targeting this receptor may enhance the efficacy of the treatment in relapsed/refractory multiple myeloma.